Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022
Objective: Traditional Chinese medicine (TCM) has been used as a complementary treatment for cancer patients, but there has been no quantitative comprehensive analysis of TCM’s efficacy. The purpose of this paper is to explore the current status and hotspots of TCM in cancer research from 2002 to 20...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1164425/full |
| _version_ | 1827909080518230016 |
|---|---|
| author | Facheng Bai Zhenguang Huang Jun Luo Yue Qiu Shuwen Huang Chenglong Huang Taotao Liu Hongliang Zhang Dandan Wang |
| author_facet | Facheng Bai Zhenguang Huang Jun Luo Yue Qiu Shuwen Huang Chenglong Huang Taotao Liu Hongliang Zhang Dandan Wang |
| author_sort | Facheng Bai |
| collection | DOAJ |
| description | Objective: Traditional Chinese medicine (TCM) has been used as a complementary treatment for cancer patients, but there has been no quantitative comprehensive analysis of TCM’s efficacy. The purpose of this paper is to explore the current status and hotspots of TCM in cancer research from 2002 to 2022 and to provide a reference for future research.Methods: We retrieved articles published between 2002 and 2022 from the Web of Science database and analyzed them using R software, VOSviewer, and CiteSpace software.Results: A total of 7,129 articles were included in this study. The publication rate of TCM cancer research increased steadily from 2002 to 2022, with a rapid increase from 2010 to 2021. China was the country with the most published articles, followed by the United States, Republic of Korea, Germany, and Japan. China was also the country with the most international collaborations, and China Medical University and Shanghai University of Traditional Chinese Medicine were the most representative cooperation centers. The Journal of Ethnopharmacology was the most published and cited journal. Apoptosis, expression, in vitro, activation, and other related keywords were commonly used in these articles. Breast cancer, colorectal cancer, gastric cancer, liver cancer, and lung cancer were the most studied cancer types in TCM research. Pathway-related apoptosis, anti-inflammation, and oxidative stress were the hotspots and trends of TCM’s anti-cancer mechanism. Metabolomics combined with network pharmacology was the main research method.Conclusion: Traditional Chinese medicine as an anti-cancer drug has received increasing attention from researchers worldwide, and it is expected to be a hotspot for developing new anti-cancer drugs in the future. Our study provides a comprehensive analysis of the current status and hotspots of TCM cancer research, which could serve as a valuable reference for future studies. |
| first_indexed | 2024-03-13T01:32:18Z |
| format | Article |
| id | doaj.art-af9e690ef6294fe59a772f9693f830d2 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-13T01:32:18Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-af9e690ef6294fe59a772f9693f830d22023-07-04T06:43:37ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-07-011410.3389/fphar.2023.11644251164425Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022Facheng Bai0Zhenguang Huang1Jun Luo2Yue Qiu3Shuwen Huang4Chenglong Huang5Taotao Liu6Hongliang Zhang7Dandan Wang8Pharmacy Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaPharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ChinaObjective: Traditional Chinese medicine (TCM) has been used as a complementary treatment for cancer patients, but there has been no quantitative comprehensive analysis of TCM’s efficacy. The purpose of this paper is to explore the current status and hotspots of TCM in cancer research from 2002 to 2022 and to provide a reference for future research.Methods: We retrieved articles published between 2002 and 2022 from the Web of Science database and analyzed them using R software, VOSviewer, and CiteSpace software.Results: A total of 7,129 articles were included in this study. The publication rate of TCM cancer research increased steadily from 2002 to 2022, with a rapid increase from 2010 to 2021. China was the country with the most published articles, followed by the United States, Republic of Korea, Germany, and Japan. China was also the country with the most international collaborations, and China Medical University and Shanghai University of Traditional Chinese Medicine were the most representative cooperation centers. The Journal of Ethnopharmacology was the most published and cited journal. Apoptosis, expression, in vitro, activation, and other related keywords were commonly used in these articles. Breast cancer, colorectal cancer, gastric cancer, liver cancer, and lung cancer were the most studied cancer types in TCM research. Pathway-related apoptosis, anti-inflammation, and oxidative stress were the hotspots and trends of TCM’s anti-cancer mechanism. Metabolomics combined with network pharmacology was the main research method.Conclusion: Traditional Chinese medicine as an anti-cancer drug has received increasing attention from researchers worldwide, and it is expected to be a hotspot for developing new anti-cancer drugs in the future. Our study provides a comprehensive analysis of the current status and hotspots of TCM cancer research, which could serve as a valuable reference for future studies.https://www.frontiersin.org/articles/10.3389/fphar.2023.1164425/fullbibliometric analysistraditional Chinese medicinecancernetwork pharmacologymetabonomic |
| spellingShingle | Facheng Bai Zhenguang Huang Jun Luo Yue Qiu Shuwen Huang Chenglong Huang Taotao Liu Hongliang Zhang Dandan Wang Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022 Frontiers in Pharmacology bibliometric analysis traditional Chinese medicine cancer network pharmacology metabonomic |
| title | Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022 |
| title_full | Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022 |
| title_fullStr | Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022 |
| title_full_unstemmed | Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022 |
| title_short | Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022 |
| title_sort | bibliometric and visual analysis in the field of traditional chinese medicine in cancer from 2002 to 2022 |
| topic | bibliometric analysis traditional Chinese medicine cancer network pharmacology metabonomic |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1164425/full |
| work_keys_str_mv | AT fachengbai bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT zhenguanghuang bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT junluo bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT yueqiu bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT shuwenhuang bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT chenglonghuang bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT taotaoliu bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT hongliangzhang bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 AT dandanwang bibliometricandvisualanalysisinthefieldoftraditionalchinesemedicineincancerfrom2002to2022 |